# A Bioequivalence Pivotal Study of SYN010 HFA Inhaler and Symbicort® 160/4.5 in Healthy Volunteers With Charcoal Block

> **NCT02850484** · PHASE1 · COMPLETED · sponsor: **Intech Biopharm Ltd.** · enrollment: 99 (actual)

## Conditions studied

- Asthma
- Chronic Obstructive Pulmonary Disease (COPD)

## Interventions

- **DRUG:** Budesonide
- **DRUG:** Formoterol

## Key facts

- **NCT ID:** NCT02850484
- **Lead sponsor:** Intech Biopharm Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-03
- **Primary completion:** 2016-05
- **Final completion:** 2016-05
- **Target enrollment:** 99 (ACTUAL)
- **Last updated:** 2016-08-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02850484

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02850484, "A Bioequivalence Pivotal Study of SYN010 HFA Inhaler and Symbicort® 160/4.5 in Healthy Volunteers With Charcoal Block". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02850484. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*